Selective interaction of lansoprazole and Astemizole with tau polymers: Potential new clinical use in diagnosis of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 19, Issue 2, 2010, Pages 573-589

  Rojo, Leonel E ^a,d   Alzate Morales, Jans ^b   Saavedra, Iván N ^a   Davies, Peter ^c   MacCioni, Ricardo B ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DE TALCA   (Chile)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSIDAD ARTURO PRAT   (Chile)

Author keywords

Alzheimer's disease; Benzimidazoles; Neurofibrillary tangles; Neuroimaging; Radiotracers; Surface plasmon resonance; Tangles; Tau aggregates

Indexed keywords

AMYLOID BETA PROTEIN; ASTEMIZOLE; HEPARIN; LANSOPRAZOLE; POLYMER; RECOMBINANT PROTEIN; TAU PROTEIN; TRACER;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; EXPERIMENTAL MOUSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; MOUSE; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; PAIRED HELICAL FILAMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SENILE PLAQUE; SURFACE PLASMON RESONANCE; ULTRAVIOLET SPECTROSCOPY;

EID: 77049090834     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1262     Document Type: Article

References (60)

1. Khachaturian ZS (1998) An overview of Alzheimer's disease research. Am J Med 104, 26S-31S; discussion 39S-42S.
2. Terry RD (2000) Where in the brain does Alzheimer's disease begin? Ann Neurol 47, 421.
3. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122.
4. Dubois B (2000) 'Prodromal Alzheimer's disease': a more useful concept than mild cognitive impairment? Curr Opin Neurol 13, 367-369.
5. Dawbarn D (1995) Neurobiology of Alzheimer's Disease, BIOS Scientific Publishers Ltd., Oxford, UK.
6. Farias GA, Vial C, Maccioni RB (1992) Specific macromolecular interactions between tau and the microtubule system. Mol Cell Biochem 112, 81-88.
7. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
8. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubuleassociated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83, 4044-4048.
9. Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, Lenzi GL, Caltagirone C, Trabucchi M, Cattabeni F, Di LucaM(2002) Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 59, 71-75. (Pubitemid 34052558)
10. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullum CM, Weiner MF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54, 139-144.
11. Hampel H, Teipel SJ (2004) Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 17, 350-354.
12. Lavados M, Farias G, Rothhammer F, Guillon M, Mujica MC, Maccioni C, Maccioni RB (2005) ApoE alleles and tau markers in patients with different levels of cognitive impairment. Arch Med Res 36, 474-479.
13. Maccioni RB, Lavados M, Guillon M, Mujica C, Bosch R, Farias G, Fuentes P (2006) Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 27, 237-244.
14. Maccioni RB, Lavados M, Maccioni CB, Mendoza-Naranjo A (2004) Biological markers of Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res 1, 307-314.
15. de Leon MJ, Klunk W (2006) Biomarkers for the early diagnosis of Alzheimer's disease. Lancet Neurol 5, 198-199.
16. Orellana DI, Quintanilla RA, Maccioni RB (2007) Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim Biophys Acta 1773, 254-263.
17. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB (2008) Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39, 1-16.
18. Rojo L, Sjoberg MK, Hernandez P, Zambrano C, Maccioni RB (2006) Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J Biomed Biotechnol 2006, 73976.
19. Sekler A, Jimenez JM, Rojo L, Pastene E, Fuentes P, Slachevsky A, Maccioni RB (2008) Cognitive impairment and Alzheimer's disease: Links with oxidative stress and cholesterol metabolism. Neuropsychiatr Dis Treat 4, 715-722.
20. Lavados M, Guillon M, Mujica MC, Rojo LE, Fuentes P, Maccioni RB (2008) Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J Alzheimers Dis 13, 225-232.
21. Maccioni RB, Cambiazo V (1995) Role of microtubuleassociated proteins in the control of microtubule assembly. Physiol Rev 75, 835-864.
22. Farias G, Gonzalez-Billault C, Maccioni RB (1997) Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau. Mol Cell Biochem 168, 59-66.
23. Gonzalez C, Farias G, MaccioniRB(1998) Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules. Cell Mol Biol (Noisy-le-grand) 44, 1117-1127.
24. Lichtenberg-Kraag B, Mandelkow EM, Biernat J, Steiner B, Schroter C, Gustke N, Meyer HE, Mandelkow E (1992) Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proc Natl Acad Sci U S A 89, 5384-5388.
25. Perez M, Arrasate M, Montejo De Garcini E, Munoz V, Avila J (2001) In vitro assembly of tau protein: mapping the regions involved in filament formation. Biochemistry 40, 5983-5991.
26. Fernandez JA, Rojo L, Kuljis RO, Maccioni RB (2008) The damage signals hypothesis of Alzheimer's disease pathogenesis. J Alzheimers Dis 14, 329-333.
27. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO (2009) The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 1153, 240-246.
28. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB (2004) Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295, 245-257.
29. Orellana DI QR, Gonzalez-Billault C, Maccioni RB (2005) Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons. Neurotox Res. 8, 295-304.
30. von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, Mandelkow EM, Davies P, Aebi U, Mandelkow E (2006) The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry 45, 6446-6457.
31. Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E (1998) Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223-10230.
32. Santa-Maria I, Perez M, Hernandez F, Avila J, Moreno FJ (2006) Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis 9, 279-285. (Pubitemid 44253346)
33. Moraga D, Rivas-Berrios A, Farias G, Wallin M, Maccioni RB (1992) Estramustine-phosphate binds to a tubulin binding domain on microtubule- associated proteins MAP-2 and tau. Biochim Biophys Acta 1121, 97-103.
34. Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H,Yamamoto T, Staufenbiel M, Yanai K, Arai H, Sasaki H, Kudo Y, Sawada T (2004) Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci 24, 2535-2541. (Pubitemid 38327966)
35. Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Fujiwara H, Nemoto M, Maruyama M, Arai H, Yanai K, Sawada T, Kudo Y (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25, 10857-10862.
36. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25, 10598-10606.
37. Du AT, Schuff N, Kramer JH, Ganzer S, Zhu XP, Jagust WJ, Miller BL, Reed BR, Mungas D, Yaffe K, Chui HC, Weiner MW (2004) Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology 62, 422-427.
38. Rusinek H, De Santi S, Frid D, Tsui WH, Tarshish CY, Convit A, de Leon MJ (2003) Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 229, 691-696.
39. Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA, deToledo-Morrell L (2005) MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 64, 1520-1524.
40. Rojo L, Chandia M, Becerra R, Avila M, Maccioni RB, (2008) in Conference on Clinical PET and Molecular Medicine (Bankok, Thailand).
41. Jicha GA, O'Donnell A, Weaver C, Angeletti R, Davies P (1999) Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. J Neurochem 72, 214-224.
42. Schaftenaar G, Noordik JH (2000) Molden: a pre-and postprocessing program for molecular and electronic structures. J Comput Aided Mol Des 14, 123-134.
43. Osguthorpe J W, Genest M and Hagler AT (1988) Proteins: Structure, Function and Genetics, Wiley-Liss, Inc., A Wiley Company.
44. Rosin CD, Belew RK, Morris GM, Olson AJ, Goodsell DS (1998) Computational coevolution of antiviral drug resistance. Artif Life 4, 41-59.
45. Avdeef A, Tsinman O (2006) PAMPA-a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur J Pharm Sci 28, 43-50.
46. Kawatake S, Nishimura Y, Sakaguchi S, Iwaki T, Doh-ura K (2006) Surface plasmon resonance analysis for the screening of anti-prion compounds. Biol Pharm Bull 29, 927-932.
47. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98, 6923-6928.
48. Sevcik J, Skrabana R, Dvorsky R, Csokova N, Iqbal K, Novak M(2007) X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease. FEBS Lett 581, 5872-5878.
49. Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62, 196-200.
50. Maccioni RB, Munoz JP, Barbeito L (2001) The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 32, 367-381.
51. Mukrasch MD, von Bergen M, Biernat J, Fischer D, Griesinger C, Mandelkow E, Zweckstetter M (2007) The "jaws" of the tau-microtubule interaction. J Biol Chem 282, 12230-12239.
52. Braak H, Braak E (1993) Entorhinal-hippocampal interaction in mnestic disorders. Hippocampus 3 Spec No, 239-246.
53. Maccioni RB GF LERRMSaRK (2008) What have we learned from tau hypothesis? In Hypotheses and Research Milestones in Alzheimer's Disease Springer-Verlag. NewYork, NewYork.
54. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12, 584-595.
55. Mattila MJ, Paakkari I (1999) Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 55, 85-93.
56. Swiader MJ, Luszczki JJ, Wielosz M, Czuczwar SJ (2005) Effect of histamine receptor antagonists on aminophyllineinduced seizures and lethality in mice. Pharmacol Rep 57, 531-535.
57. Norris CH, Jackson RT (1987) Inhibition by astemizole of activity from the isolated semicircular canal. Arch Otolaryngol Head Neck Surg 113, 981-983.
58. Hatlebakk JG, Nesje LB, Hausken T, Bang CJ, Berstad A (1995) Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol 30, 1053-1057.
59. Cheng FC, Ho YF, Hung LC, Chen CF, Tsai TH (2002) Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J Chromatogr A 949, 35-42.
60. Rich RL, Myszka DG (2001) BIACORE J: a new platform for routine biomolecular interaction analysis. J Mol Recognit 14, 223-228.